Background: To evaluate the reversal effect of high dose tamoxifen on multidrug resistance to EP regimen in patients with non-small cell lung cancer.
Methods: A total of 41 patients with NSCLC were studied, who were resistant to EP regimen and were proved to have P-gp protein overexpression. All patients were randomizedly divided into two arms. Reversal group (n=21) received oral tamoxifen 100?mg, 2 times everyday on D1-5, together with EP regimen. Control group (n=20) were only given EP regimen.
Results: In reversal group, complete response occurred in 1 patient, and partial response in 5; disease remained stable in 11 patients, and tumor progression occurred in 4 patients. The response rate was 28.6%(6/21). In control group, no response occurred; 9 patients had stable diseases, and the other 11 progressed. There was a significant difference in response rate between the two groups (P=0.012?1). In reversal and control groups, the median survivals were 8.4 and 4.6 months respectively (P < 0.01), and 1-year survial rates were 38.1% and 35.0% respectively. Reversal of P-gp occurred in 7 cases of reversal group (33.3%),and none in control group (P= 0.005?2) . There was no significant difference in toxicities between the two groups (P > 0.05).
Conclusions: High dose tamoxifen can remarkably downregulate the expression of P-gp and partially reverse the multidrug resistance to EP regimen for non-small cell lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3779/j.issn.1009-3419.2002.03.13 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Passive amylin immunotherapy improves brain function and reduces brain β‐amyloid pathology in APP/PS1 mice.
Alzheimers Dement
December 2024
University of Kentucky, Lexington, KY, USA
Background: Amylin is a systemic hormone that is co‐secreted with insulin from pancreatic β‐cells. Amylin co‐aggregates with brain parenchymal and vascular β‐amyloid in persons with Alzheimer’s dementia. The present pilot study sought to assess the safety and side effects during and after the treatment period of passive amylin immunotherapy in the APP/PS1 mouse model of Alzheimer’s disease.
View Article and Find Full Text PDFSystemic Medications and Their Ocular Side Effects.
Cureus
December 2024
Department of Clinical Research, Clinical Virtual Research Center, Wayne, USA.
Most of the drugs that we use in our everyday clinic cause ocular side effects or toxicity, depending on the drug duration and dose. Eye care physicians should be familiar with any possible ocular side effects linked to these medications, which could save the physicians' time to determine the diagnosis of the ocular irritation or toxicity. Not all medications are listed in this review, but we did go over the most common systemic medications based on our experience seeing patients in our everyday clinic.
View Article and Find Full Text PDFExpression of nicastrin, NICD1, and Hes1 in NCSTN knockout mice: implications for hidradenitis suppurativa, Alzheimer's, and liver cancer.
Eur J Med Res
December 2024
Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, No. 7 Weiwu, Zhengzhou, 450003, Henan, China.
Background: Nicastrin, a subunit of the γ-secretase complex, is encoded by the NCSTN gene and regulates notch signaling, it is involved in the pathogenesis of hidradenitis suppurativa (HS), Alzheimer disease (AD), and liver cancer. However, the animal models for studying HS are relatively scarce.
Methods: CRISPR/Cas-mediated genetic engineering was used to generate targeted knockout offspring mice (C57BL/6J).
Selecting the Right Dose to Move Breast Cancer Prevention Forward.
Cancer Prev Res (Phila)
December 2024
Division of Medical Oncology, Department of Medicine, E.O. Ospedali Galliera, Genoa, Italy.
Article Synopsis
- Low uptake and adherence to breast cancer preventive therapy are primarily due to fears of serious side effects and menopausal symptoms.
- A study indicates that low-dose tamoxifen is effective and has fewer side effects for high-risk women, leading to better patient adherence.
- More than 70% of women who were counseled about low-dose tamoxifen continued taking it after one year, suggesting this treatment could improve breast cancer prevention efforts and lower related mortality rates.
Low-dose tamoxifen treatment reduces collagen organisation indicative of tissue stiffness in the normal breast: results from the KARISMA randomised controlled trial.
Breast Cancer Res
November 2024
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, 171 77, Solna, Sweden.
Background: Tissue stiffness, dictated by organisation of interstitial fibrillar collagens, increases breast cancer risk and contributes to cancer progression. Tamoxifen is a standard treatment for receptor-positive breast cancer and is also aproved for primary prevention. We investigated the effect of tamoxifen and its main metabolites on the breast tissue collagen organisation as a proxy for stiffness and explored the relationship between mammographic density (MD) and collagen organisation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!